MX2021003274A - Combinacion farmaceutica para el tratamiento de cancer. - Google Patents
Combinacion farmaceutica para el tratamiento de cancer.Info
- Publication number
- MX2021003274A MX2021003274A MX2021003274A MX2021003274A MX2021003274A MX 2021003274 A MX2021003274 A MX 2021003274A MX 2021003274 A MX2021003274 A MX 2021003274A MX 2021003274 A MX2021003274 A MX 2021003274A MX 2021003274 A MX2021003274 A MX 2021003274A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- pharmaceutical combination
- antagonist
- sfrp2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención proporciona una combinación farmacéutica que comprende un antagonista de SFRP2 y un antagonista del anticuerpo PD-1. La invención también proporciona un método para el tratamiento del cáncer, que comprende la administración de una cantidad terapéuticamente eficaz de un antagonista de SFRP2 y un antagonista de PD-1 a un paciente que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862737155P | 2018-09-27 | 2018-09-27 | |
PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003274A true MX2021003274A (es) | 2021-09-28 |
Family
ID=69953118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003274A MX2021003274A (es) | 2018-09-27 | 2019-09-27 | Combinacion farmaceutica para el tratamiento de cancer. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210395351A1 (es) |
EP (1) | EP3856784A4 (es) |
JP (1) | JP7451506B2 (es) |
KR (1) | KR20210065146A (es) |
CN (1) | CN113454114A (es) |
AU (1) | AU2019351267A1 (es) |
BR (1) | BR112021005525A2 (es) |
CA (1) | CA3114173A1 (es) |
IL (1) | IL281782A (es) |
MX (1) | MX2021003274A (es) |
SG (1) | SG11202102865WA (es) |
WO (1) | WO2020069439A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2285989B1 (en) | 2008-05-15 | 2016-11-16 | The University of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
WO2014022774A1 (en) * | 2012-08-02 | 2014-02-06 | Fred Hutchinson Cancer Research Center | Treatment induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
FI3313441T3 (fi) | 2015-06-24 | 2024-03-28 | Janssen Biotech Inc | Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
EP3964529A1 (en) * | 2016-01-22 | 2022-03-09 | Mabquest SA | Non-blocking pd1 specific antibodies |
EP3582811B1 (en) | 2017-02-14 | 2024-07-10 | Novartis AG | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
-
2019
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 CN CN201980076608.3A patent/CN113454114A/zh active Pending
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/ja active Active
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
- 2019-09-27 KR KR1020217012004A patent/KR20210065146A/ko unknown
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/pt unknown
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/es unknown
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en unknown
- 2019-09-27 AU AU2019351267A patent/AU2019351267A1/en active Pending
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7451506B2 (ja) | 2024-03-18 |
CA3114173A1 (en) | 2020-04-02 |
SG11202102865WA (en) | 2021-04-29 |
WO2020069439A1 (en) | 2020-04-02 |
BR112021005525A2 (pt) | 2021-06-29 |
JP2022502434A (ja) | 2022-01-11 |
US20210395351A1 (en) | 2021-12-23 |
AU2019351267A1 (en) | 2021-05-13 |
CN113454114A (zh) | 2021-09-28 |
EP3856784A1 (en) | 2021-08-04 |
EP3856784A4 (en) | 2022-10-19 |
IL281782A (en) | 2021-05-31 |
KR20210065146A (ko) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502545A1 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2016008362A (es) | Combinaciones farmaceuticas. | |
MX2020010144A (es) | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). | |
MX2019011148A (es) | Metodos de tratamiento. | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
PH12016502354A1 (en) | Pharmaceutical composition | |
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
PH12016502352A1 (en) | Pharmaceutical composition | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia |